Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation.
- DOI
- 10.1136/bmjnph-2023-000776
- Published
- 2025
- Container
- BMJ nutrition, prevention & health
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjnph-2023-000776,
title = {Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation.},
author = {Raghavan K and Dedeepiya VD and Yamamoto N and Ikewaki N and Iwasaki M and Dinassing A and Senthilkumar R and Preethy S and Abraham SJK},
year = {2025},
journal = {BMJ nutrition, prevention \& health},
doi = {10.1136/bmjnph-2023-000776},
url = {https://doi.org/10.1136/bmjnph-2023-000776}
}RIS
TY - JOUR TI - Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation. AU - Raghavan K AU - Dedeepiya VD AU - Yamamoto N AU - Ikewaki N AU - Iwasaki M AU - Dinassing A AU - Senthilkumar R AU - Preethy S AU - Abraham SJK PY - 2025 JO - BMJ nutrition, prevention & health DO - 10.1136/bmjnph-2023-000776 UR - https://doi.org/10.1136/bmjnph-2023-000776 ER -
APA
K, R., VD, D., N, Y., N, I., M, I., A, D., R, S., S, P., & SJK, A. (2025). Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation.. BMJ nutrition, prevention & health. https://doi.org/10.1136/bmjnph-2023-000776
Source records
- pubmed · retrieved 2026-09-26T12:58:40.712Z